pazopanib (VOTRIENT)

Diagnoses Considered for Coverage:

- Advanced renal cell carcinoma
- Soft tissue sarcoma (STS)
- Advanced thyroid gland carcinoma
- Advanced gastrointestinal stromal tumors (GIST)
- Uterine sarcoma
- Chondrosarcoma (bone cancer)

Coverage Criteria:

For diagnosis of advanced renal cell carcinoma:

- Being used as single-agent therapy, **and**
- Dose does not exceed 800 mg per day.

For diagnosis of advanced soft tissue sarcoma (excluding adipocytic soft tissue sarcoma and GIST):

- Dose does not exceed 800 mg per day, **and**
- One of the following:
    - Being used as a single-agent therapy or in combination with gemcitabine for angiosarcoma, or
    - Being used as single-agent subsequent therapy in advanced or metastatic disease or provider attestation that patient is ineligible for IV systemic therapy, or
    - Being used as a single-agent therapy for one of the following STS subtypes:
        i. Alveolar soft part sarcoma (ASPS), or
        ii. Solitary Fibrous tumor, or
        iii. Desmoid Tumors (Aggressive Fibromatosis), or
        iv. Dermatofibrosarcoma protuberans (DFSP), or
        v. Rhabdomyosarcoma

For diagnosis of thyroid gland carcinoma:

- Dose does not exceed 800 mg per day, **and**
- One of the following:
    a) For medullary disease: Disease progression on one of the following first line systemic therapy [e.g. Calpresa (vandetanib) or Cometriq (cabozantinib)]
    OR

b) For advanced differentiated (follicular, papillary, and Hurthle type) disease: Inadequate response, or intolerable side effect, or contraindication to Lenvima (lenvatinib) or Nexavar (sorafenib)

For diagnosis of advanced gastrointestinal stromal tumors (GIST):

- One of the following:
  - Disease progression after single-agent therapy of all the following:
    - imatinib (Gleevec),
    - sunitinib (Sutent),
    - regorafenib (Stivarga),
    - ripretinib (Qinlock),

    OR
  - *Disease is unresectable succinate dehydrogenase (SDH)-deficient GIST,*

  and
- Being used as a single-agent therapy, **and**
- Dose does not exceed 800 mg per day.

For diagnosis of uterine sarcoma:

- Patient has recurrent or metastatic disease, **and**
- Disease has progressed despite prior cytotoxic chemotherapy therapy, **and**
- Being used as a single-agent therapy, **and**
- Dose does not exceed 800 mg per day.

For diagnosis of chordoma:

- Patient has recurrent or metastatic disease, **and**
- Being used as a single-agent therapy, **and**
- Dose does not exceed 800 mg per day.

Coverage Duration: one year

Effective Date: 04/03/2024